Shimoi, Tatsunori
Nagai, Shigenori E.
Yoshinami, Tetsuhiro
Takahashi, Masato
Arioka, Hitoshi
Ishihara, Mikiya
Kikawa, Yuichiro
Koizumi, Kei
Kondo, Naoto
Sagara, Yasuaki
Takada, Masahiro
Takano, Toshimi
Tsurutani, Junji
Naito, Yoichi
Nakamura, Rikiya
Hattori, Masaya
Hara, Fimikata
Hayashi, Naoki
Mizuno, Toshiro
Miyashita, Minoru
Yamashita, Nami
Yamanaka, Takashi
Saji, Shigehira
Iwata, Hiroji
Toyama, Tatsuya
Article History
Received: 13 January 2020
Accepted: 26 March 2020
First Online: 2 April 2020
Change Date: 22 April 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12282-021-01252-x
Compliance with ethical standards
:
: T. Toyama received research funding from Chugai, Novartis Pharma and Eisai, and honoraria from AstraZeneca. MT received research funding from Eisai, Kyowa Kirin, Nippon Kayaku and Taiho and honoraria from AstraZeneca, Eisai, Eli Lilly and Pfizer. KK received honoraria from Pfizer, Chugai, Eisai, Eli Lilly, Novartis Pharma, AstraZeneca, Merck Serono, Genomic Health, Allergan Japan, Kyowa Kirin, Daiichi Sankyo, and Taiho. HA received honoraria from Novartis Pharma, Taiho, Nippon Kayaku, Chugai, MSD, Takeda, Sanofi, Ono, Pfizer, Eisai, Kyowa Kirin and Mochida, and research funds from Taiho, Chugai and Kyowa Kirin. MT received honoraria from Chugai, AstraZeneca, Pfizer, Eli Lilly, Eisai, Daiichi Sankyo, and Kyowa Kirin, and research funding from AstraZeneca, Eisai, and Daiichi Sankyo. T. Takano received research funding from Daiichi Sankyo, Kyowa Kirin, Eisai, Ono, Bristol-Myers Squibb, MSD, Merck Serono, Taiho, Novartis Pharma, and Chugai, and honoraria from Daiichi Sankyo, Kyowa Kirin, Eisai, Pfizer, and Eli Lilly. YN received honoraria from Pfizer, Chugai, Eisai, Eli Lilly, Taiho, Fuji film, Toyama Kagaku, Novartis Pharma, Nippon Kayaku, AstraZeneca, Merck Serono, Bayer, Roche, and Meiji Seika, and research funding from Roche Merck Serono, AstraZeneca, Eli Lilly, Nippon Kayaku, Pfizer, and Taiho. TY received honoraria from Chugai Pharma, Kyowa Kirin, Novartis Pharma, and Pfizer. NK reports honoraria from Chugai, AstraZeneca, Eisai, Pfizer, and Novartis Pharma. MI received honoraria from Chugai, Eisai, Pfizer, MSD, and Takara Bio. YK received honoraria from Eisai, Novartis Pharma, Pfizer, Chugai, AstraZeneca, and Taiho. SN received honoraria from Chugai, Novartis Pharma, Pfizer, Eli Lilly, Eisai, and Taiho and research funding from Chugai and Nippon Kayaku. TY received honoraria from Eisai, Chugai, Daiichi Sankyo, Novartis Pharma, Pfizer, and Taiho. SS received honoraria from Eisai, Chugai, Astra Zeneca, Takeda, Novartis Pharma, Taiho, Kyowa Kirin, Pfizer, Daiichi Sankyo, Nihon Kayaku, and Ono and research funding from Eisai, Chugai, Astra Zeneca, Takeda, Taiho and Ono. SS is the executive board member of JBCS and JBCRG. HI received honoraria from Chugai, Astra Zeneca, MDS, Novartis Pharma, Kyowa Kirin, Pfizer, Daiichi Sankyo, and Eli Lilly and research funding from Chugai, Novartis Pharma, MDS, and Eli Lilly. The other authors declare no relevant conflicts of interest.